A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)
In this study, participants with advanced or metastatic adenocarcinoma or squamous cell
carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction
(EGJ) that has progressed after first-line standard therapy will be randomized to receive
either single agent pembrolizumab or the Investigator's choice of standard therapy with
paclitaxel, docetaxel, or irinotecan. The primary study hypothesis is that treatment with
pembrolizumab will prolong progression-free survival (PFS) and/or overall survival (OS) as
compared to treatment with standard therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society